Early breast cancer represents a heterogeneous disease entity, that can be further categorized by the use of simple immunohistochemical (IHC) molecular markers, including the estrogen receptor (ER), the progesterone receptor (PgR), the epidermal growth factor receptor (EGFR), the c-erbB2 (HER2/neu) receptor, the mitotic index Ki67 and the cytokeratines 5/6 [2]. Here, ERBB2 is linked to breast carcinoma.